Gilead’s HIV prevention pill cost widespread use, study finds

TAccording to a new analysis by US government researchers, increasing costs of the only HIV prevention pill may hinder widespread use in recent years, raising longstanding concerns over the ability to erase the virus.

From 2014 to 2018, the total payments made by government programs, commercial insurers and patients for Truvada, which were approved to prevent HIV in 2012, increased from $ 114 million to nearly $ 2.1 billion. Yet the number of people who were given prescriptions in 2018 was just 204,700, which was less than 20% by estimate.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days!

get started

Leave a Reply